- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01068587
MET/VEGFR2 Inhibitor GSK1363089 and Erlotinib Hydrochloride or Erlotinib Hydrochloride Alone in Locally Advanced or Metastatic NSCLC That Has Not Responded to Previous Chemotherapy
A Phase I/II Study of Foretinib in Patients With Previously Treated Non-Small Cell Lung Cancer Receiving Standard Erlotinib Therapy
RATIONALE: MET/VEGFR2 inhibitor Foretinib and erlotinib hydrochloride may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor.
PURPOSE: This randomized phase I/II trial is studying the side effects of erlotinib hydrochloride when given together with or without MET/VEGFR2 inhibitor Foretinib and to see how well it works in treating patients with locally advanced or metastatic non-small cell lung cancer that has not responded to previous chemotherapy.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
OBJECTIVES:
- To determine the recommended phase II dose of MET/VEGFR2 inhibitor Foretinibin combination with standard erlotinib hydrochloride therapy in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) after failure of at least one prior chemotherapy regimen, and whose EGFR-expression status is positive or unknown.
- To determine the safety, tolerability, toxicity profile, dose-limiting toxicities, and pharmacokinetic profile of MET/VEGFR2 inhibitor Foretinib and erlotinib hydrochloride in this schedule.
- To determine the correlation, if any, between the toxicity profile and pharmacokinetics.
- To assess the anti-tumor activity of MET/VEGFR2 inhibitor Foretinib in combination with erlotinib hydrochloride as evidenced by response rates, clinical benefit (complete or partial response or stable disease ≥ 8 weeks duration), and an exploratory endpoint of early assessment of tumor size as a continuous variable (when compared to erlotinib hydrochloride alone).
- To assess one-year survival rate in these patients.
- To investigate the correlation, if any, between response and biomarkers, including EGFR gene mutation, EGFR gene amplification, EGFR gene polymorphisms, c-Met gene mutation, amplification and expression, phospho-c-Met expression, K-Ras gene mutation, and baseline serum HGF levels.
OUTLINE: This is a multicenter, dose-escalation phase I study of MET/VEGFR2 inhibitor Foretinib followed by a randomized, open-label phase II study.
- Phase I (dose-escalation) : Patients receive oral erlotinib hydrochloride once daily on days 1-28. Patients receive oral MET/VEGFR2 inhibitor GSK1363089 once daily on days 15-28 during course 1 and on days 1-28 during all other courses. Courses repeat every 28 days until the maximum-tolerated dose of MET/VEGFR2 inhibitor Foretinib is determined.
Blood samples are collected on days 14 and 28 of course 1 for pharmacokinetics and day 1 of courses 1 and 2 and post treatment for pharmacodynamic studies.
Phase II: Patients are randomized to 1 of 2 treatment arms:
- Arm I (MET/VEGFR2 inhibitor Foretinib and erlotinib hydrochloride): Patients receive oral MET/VEGFR2 inhibitor Foretinib (at the recommended phase II dose determined in phase I) once daily and oral erlotinib hydrochloride once daily on days 1-28. Courses repeat very 28 days in the absence of disease progression or unacceptable toxicity.
- Arm II (erlotinib hydrochloride only): Patients receive oral erlotinib hydrochloride once daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
In both arms, samples are collected for pharmacodynamic studies as in phase I.
After completion of study treatment, patients are followed at week 4 and then every 3 months thereafter.
Study Type
Enrollment (Actual)
Phase
- Phase 2
- Phase 1
Contacts and Locations
Study Locations
-
-
British Columbia
-
Vancouver, British Columbia, Canada, V5Z 4E6
- BCCA - Vancouver Cancer Centre
-
-
Ontario
-
Hamilton, Ontario, Canada, L8V 5C2
- Juravinski Cancer Centre at Hamilton Health Sciences
-
Ottawa, Ontario, Canada, K1H 8L6
- Ottawa Health Research Institute - General Division
-
Toronto, Ontario, Canada, M5G 2M9
- Univ. Health Network-Princess Margaret Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
DISEASE CHARACTERISTICS:
Histologically or cytologically confirmed non-small cell lung cancer (NSCLC), meeting all of the following criteria:
- Locally advanced or metastatic disease
Failed 1-2 prior chemotherapy regimen
- Must be eligible to receive erlotinib therapy (i.e., patients must have received 1-2 prior chemotherapy regimen [combination unless patient is ≥ 70 years]) for advanced or metastatic disease
- No plan to receive further palliative cytotoxic chemotherapy
EGFR-expression status positive or unknown
- Patients who are known to have tumors that are EGFR negative on IHC are not eligible
Presence of clinically and/or radiologically documented measurable disease
At least 1 site of disease must be unidimensionally measurable as follows:
- Chest X-ray ≥ 20 mm
- CT scan (with slice thickness of ≤ 5 mm) ≥ 10 mm (longest diameter)
- Physical exam (using calipers) ≥ 10 mm
- Lymph nodes by CT scan ≥ 15 mm (measured in short axis)
- Measurable lesions must be outside a previous radiotherapy field unless disease progression has been documented
- Must have archival tissue available or undergo a biopsy or FNA prior to registration/ randomization
No appreciable cavitation in central thoracic lesions
- Patients with overt bleeding from any site (> 30 mL bleeding/episode) within 3 months of study entry are not eligible
No untreated brain or meningeal metastases (CT scans are not required to rule this out unless there is a clinical suspicion of CNS disease)
- Patients with treated and radiologic or clinical evidence of stable brain metastases, with no evidence of cavitation or hemorrhage in the brain lesion, are eligible providing that they are asymptomatic and do not require corticosteroids (must have discontinued steroids ≥ 1 week prior to entry)
PATIENT CHARACTERISTICS:
- ECOG performance status 0-2
- Patients must have discontinued smoking for ≥ 2 weeks prior to registration, and must be prepared to refrain from cigarette usage until completion of the pharmacokinetic sampling at the end of study course 1 (approximately 6 weeks in total) (Phase I only)
- Granulocyte count (AGC) ≥ 1.5 times 10^9/L
- Platelet count ≥ 100 x 10^9/L
- Serum creatinine ≤ 1.5 times upper normal limit (UNL) OR calculated creatinine clearance ≥ 50 mL/min (≥ 0.83 mL/sec)
- Bilirubin ≤ 1.5 times UNL
- ALT and AST ≤ 2 times UNL
No clinically relevant hemoptysis (> 5 mL fresh blood) within 4 weeks prior to study entry
- Patients with only flecks of blood in sputum are permitted
- No other invasive malignancies, unless curatively treated with no evidence of disease
- Not pregnant or nursing
- Negative pregnancy test
- Fertile patients must use effective contraception during and for 90 days after completion of study therapy
No untreated and/or uncontrolled cardiovascular conditions and/or have symptomatic cardiac dysfunction, including any of the following:
- Unstable angina, congestive heart failure, or myocardial infarction within the previous year
- Cardiac ventricular arrhythmias requiring medication
- History of 2nd or 3rd degree atrioventricular conduction defects
- Patients with a significant cardiac history (even if controlled) or prior doxorubicin exposure are required to have a LVEF > 50%
- Patients with proliferative diabetic retinopathy, retinal arteritis, or hemorrhage must undergo full ophthalmological examination prior to entry to this study
- Must have resting systolic BP ≤ 150 mm Hg and/or diastolic BP ≤ 100 mm Hg (in the presence or absence of a stable dose of anti-hypertensive medication)
- No poorly controlled hypertension
- No history of labile hypertension or poor compliance with anti-hypertensive medication
No GI tract disease resulting in an inability to absorb oral medication, including any of the following situations:
- Uncontrolled inflammatory GI disease (e.g., Crohn's disease, ulcerative colitis)
- Post-surgical malabsorption characterized by uncontrolled diarrhea that results in weight loss and vitamin deficiency or requires IV hyperalimentation (use of pancreatic enzyme supplementation is allowed)
- No active or uncontrolled infections
- No serious illnesses or medical conditions that would not permit the patient to be managed according to the protocol
- No known hypersensitivity to the study drugs or their components
PRIOR CONCURRENT THERAPY:
- See Disease Characteristics
- No more than two prior chemotherapy regimens for metastatic NSCLC (excluding adjuvant chemotherapy)
Recovered from any treatment-related toxicities prior to randomization
- Persistent cisplatin- or taxane-induced sensory neuropathy ≤ grade 2 is acceptable
- No prior therapy with agents acting on the EGFR pathway
- No prior therapy with a c-Met inhibitor
- At least 21 days since the last dose of chemotherapy
At least 21 days since last fraction of prior radiation therapy
- Exceptions may be made for non-myelosuppressive radiation to peripheral areas
- More than 14 days since prior major surgery, provided that wound healing has occurred
- More than 3 weeks since prior and no other concurrent investigational drugs or anti-cancer therapy
No concurrent CYP3A4 enzyme inducing or inhibiting drugs known to interact with erlotinib hydrochloride, including any of the following:
- Enzyme-inducing anticonvulsants
- Rifampicin
- Rifabutin
- St. John wort
- Atazanavir
- Ketoconazole
- Patients with a history of pulmonary embolus or a deep vein thrombosis diagnosed and/or treated within 6 months prior to registration will be excluded.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Erlotinib
|
erlotinib PO daily dosing starting cycle 1 day 1.
Recommended Phase II dose to be determine in Phase I.
Tumour markers alone cannot be used to assess objective tumour response.
If markers are initially above the upper normal limit, however, they must normalize for a patient to be considered in complete response
|
Active Comparator: Foretinib plus Erlotinib
|
erlotinib PO daily dosing starting cycle 1 day 1.
Recommended Phase II dose to be determine in Phase I.
Tumour markers alone cannot be used to assess objective tumour response.
If markers are initially above the upper normal limit, however, they must normalize for a patient to be considered in complete response
PhaseI and Phase II Arm A: Foretinib PO daily dosing starting cycle 1 day 15 and erlotinib PO daily dosing starting cycle 1 day 1. Recommended Phase II dose to be determine in Phase I. |
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
The recommended phase II dose of daily oral MET/VEGFR2 inhibitor Foretinib when given in combination with standard erlotinib hydrochloride therapy (phase I)
Time Frame: 3 years
|
After completion of Phase I portion of the study
|
3 years
|
Safety, tolerability, dose-limiting toxicities, and pharmacokinetic profile (phase I)
Time Frame: 3 years
|
Assessed from the time of first dose.
Results will be analyzed at time of final analysis
|
3 years
|
Correlation between toxicity and pharmacokinetics (phase I)
Time Frame: 3 years
|
After completion of phase I
|
3 years
|
Objective tumor response rate (partial or complete response) (phase II)
Time Frame: After every second cycle
|
After every second cycle
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Clinical benefit (complete response, partial response, and stable disease for ≥ 8 weeks) (phase II)
Time Frame: 8 weeks
|
End of every second cycle
|
8 weeks
|
Tumor size at 8 weeks (phase II)
Time Frame: 8 weeks
|
At end of second cycle.
|
8 weeks
|
1-year survival rate (phase II)
Time Frame: 1 year
|
1 year
|
|
Response or stable disease duration (phase II)
Time Frame: After progression
|
After progression
|
|
Progression-free survival (phase II)
Time Frame: 3 years
|
After completion of therapy
|
3 years
|
Toxicity (phase II)
Time Frame: 3 years
|
From the time of 1st dose and will be assessed overall at the time of final analysis
|
3 years
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Study Chair: Natasha Leighl, MD, FRCPC, Princess Margaret Hospital, Canada
- Study Chair: Cheryl Ho, MD, British Columbia Cancer Agency
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimated)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- I196
- CAN-NCIC-IND196 (Other Identifier: PDQ)
- GSK-CAN-NCIC-IND196 (Other Identifier: GlaxoSmithKline)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Lung Cancer
-
M.D. Anderson Cancer CenterRecruitingStage III Lung Cancer AJCC v8 | Lung Carcinoma | Stage II Lung Cancer AJCC v8 | Stage IIA Lung Cancer AJCC v8 | Stage IIB Lung Cancer AJCC v8 | Stage IIIA Lung Cancer AJCC v8 | Stage IIIB Lung Cancer AJCC v8 | Stage I Lung Cancer AJCC v8 | Stage IA1 Lung Cancer AJCC v8 | Stage IA2 Lung Cancer AJCC v8 | Stage... and other conditionsUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)Active, not recruitingStage IVA Lung Cancer AJCC v8 | Stage IVB Lung Cancer AJCC v8 | Stage III Lung Cancer AJCC v8 | Stage IV Lung Cancer AJCC v8 | Stage II Lung Cancer AJCC v8 | Stage IIA Lung Cancer AJCC v8 | Stage IIB Lung Cancer AJCC v8 | Stage IIIA Lung Cancer AJCC v8 | Stage IIIB Lung Cancer AJCC v8 | Stage I Lung Cancer... and other conditionsUnited States
-
Roswell Park Cancer InstituteNational Cancer Institute (NCI)RecruitingStage II Lung Cancer AJCC v8 | Stage IIA Lung Cancer AJCC v8 | Stage IIB Lung Cancer AJCC v8 | Stage IIIA Lung Cancer AJCC v8 | Stage IIIB Lung Cancer AJCC v8 | Stage I Lung Cancer AJCC v8 | Stage IA1 Lung Cancer AJCC v8 | Stage IA2 Lung Cancer AJCC v8 | Stage IA3 Lung Cancer AJCC v8 | Stage IB Lung Cancer...United States
-
Dana-Farber Cancer InstituteMedWaves, IncNot yet recruitingLung Cancer | Lung Cancer Stage I | Lung Cancer Stage II | Stage I Lung Cancer | Stage I - II Primary Lung Cancer | Stage II Lung CancerUnited States
-
City of Hope Medical CenterNational Cancer Institute (NCI)Active, not recruitingCaregiver | Stage III Lung Cancer AJCC v7 | Stage I Lung Cancer AJCC v7 | Stage II Lung Cancer AJCC v7 | Stage IB Lung Cancer AJCC v7 | Stage IA Lung Cancer AJCC v7 | Stage IIA Lung Cancer AJCC v7 | Stage IIB Lung Cancer AJCC v7 | Stage IIIA Lung Cancer AJCC v7 | Stage IIIB Lung Cancer AJCC v7United States
-
WindMIL TherapeuticsBristol-Myers SquibbTerminatedNSCLC | Lung Cancer | Lung Cancer Metastatic | Lung Cancer, Non-small Cell | Non Small Cell Lung Cancer | Non-small Cell Lung Cancer | Non-small Cell Lung Cancer Metastatic | Non Small Cell Lung Cancer MetastaticUnited States
-
University of Southern CaliforniaNational Cancer Institute (NCI); Genentech, Inc.RecruitingStage IVA Lung Cancer AJCC v8 | Stage IVB Lung Cancer AJCC v8 | Lung Non-Small Cell Carcinoma | Stage III Lung Cancer AJCC v8 | Stage IV Lung Cancer AJCC v8 | Stage II Lung Cancer AJCC v8 | Stage IIA Lung Cancer AJCC v8 | Stage IIB Lung Cancer AJCC v8 | Stage IIIA Lung Cancer AJCC v8 | Stage IIIB Lung... and other conditionsUnited States
-
Emory UniversityNational Cancer Institute (NCI)TerminatedLung Non-Small Cell Carcinoma | Stage II Lung Cancer AJCC v8 | Stage IIA Lung Cancer AJCC v8 | Stage IIB Lung Cancer AJCC v8 | Stage IIIA Lung Cancer AJCC v8 | Stage I Lung Cancer AJCC v8 | Stage IA1 Lung Cancer AJCC v8 | Stage IA2 Lung Cancer AJCC v8 | Stage IA3 Lung Cancer AJCC v8 | Stage IB Lung Cancer...United States
-
University of California, San FranciscoMerck Sharp & Dohme LLCWithdrawnLung Non-Small Cell Carcinoma | Stage II Lung Cancer AJCC v8 | Stage IIA Lung Cancer AJCC v8 | Stage IIB Lung Cancer AJCC v8 | Stage IIIA Lung Cancer AJCC v8 | Stage I Lung Cancer AJCC v8 | Stage IA1 Lung Cancer AJCC v8 | Stage IA2 Lung Cancer AJCC v8 | Stage IA3 Lung Cancer AJCC v8 | Stage IB Lung Cancer...United States
-
City of Hope Medical CenterNational Cancer Institute (NCI)CompletedStage IVA Lung Cancer AJCC v8 | Stage IVB Lung Cancer AJCC v8 | Stage III Lung Cancer AJCC v8 | Metastatic Lung Carcinoma | Stage IV Lung Cancer AJCC v8 | Head and Neck Carcinoma | Lung Carcinoma | Stage II Lung Cancer AJCC v8 | Stage IIA Lung Cancer AJCC v8 | Stage IIB Lung Cancer AJCC v8 | Stage IIIA Lung... and other conditionsUnited States
Clinical Trials on erlotinib hydrochloride
-
AVEO Pharmaceuticals, Inc.Biodesix, Inc.TerminatedNon-small Cell Lung CancerKorea, Republic of, United States, Australia, Taiwan, Singapore, Hong Kong, Italy
-
M.D. Anderson Cancer CenterCompletedAdvanced CancersUnited States
-
University of ChicagoNational Cancer Institute (NCI)CompletedMalignant Peritoneal MesotheliomaUnited States
-
University of California, DavisNational Cancer Institute (NCI); Novartis PharmaceuticalsCompletedRecurrent Non-small Cell Lung CancerUnited States
-
Merck Sharp & Dohme LLCCompleted
-
European Organisation for Research and Treatment...CompletedOvarian Cancer | Fallopian Tube Cancer | Primary Peritoneal Cavity CancerFrance, Spain, Netherlands, Australia, United Kingdom, Italy, Portugal, Austria
-
Sidney Kimmel Comprehensive Cancer Center at Johns...National Cancer Institute (NCI)CompletedHead and Neck CancerSpain, United States
-
National Cancer Institute (NCI)NCIC Clinical Trials GroupCompletedEndometrial CancerCanada
-
Southwest Oncology GroupNational Cancer Institute (NCI)CompletedGastric Cancer | Esophageal CancerUnited States, Canada
-
The Cleveland ClinicUnknownBrain and Central Nervous System TumorsUnited States